Khemankari Life Sciences Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 17-07-2024
- Paid Up Capital ₹ 0.20 M
as on 17-07-2024
- Company Age 6 Year, 11 Months
- Last Filing with ROC 31 Mar 2023
- Revenue 2710.71%
(FY 2022)
- Profit 3608.72%
(FY 2022)
- Ebitda 1048.18%
(FY 2022)
- Net Worth 26.82%
(FY 2022)
- Total Assets 26.75%
(FY 2022)
About Khemankari Life Sciences
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.20 M, as per Ministry of Corporate Affairs (MCA) records.
Rajib Purakayastha and Saraswati Purakayastha serve as directors at the Company.
- CIN/LLPIN
U74999WB2017PTC224071
- Company No.
224071
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
28 Dec 2017
- Date of AGM
21 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Kolkata
Industry
Company Details
- Location
Kolkata, West Bengal, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Khemankari Life Sciences Private Limited offer?
Khemankari Life Sciences Private Limited offers a wide range of products and services, including Digestive System Drugs & Medicines, Gastrointestinal Drugs, Repair & Maintenance Services, Machinery Repairs, Surgical & ICU Equipments, Oxygen Cylinder, Gas Cylinders and Accessories, Gas Cylinders, Carts, Dollies & Trolleys, Cylinder Trolley.
Who are the key members and board of directors at Khemankari Life Sciences?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Rajib Purakayastha  | Director | 28-Dec-2017 | Current |
| Saraswati Purakayastha | Director | 28-Dec-2017 | Current |
Financial Performance of Khemankari Life Sciences.
Khemankari Life Sciences Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 2710.71% increase. The company also saw a substantial improvement in profitability, with a 3608.72% increase in profit. The company's net worth Soared by an impressive increase of 26.82%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Khemankari Life Sciences?
In 2022, Khemankari Life Sciences had a promoter holding of 84.00% and a public holding of 16.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Khemankari Life Sciences?
Unlock and access historical data on people associated with Khemankari Life Sciences, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Khemankari Life Sciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Khemankari Life Sciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
